Connect with us

BioPharma

Marketing Worldwide Corp (OTCMKTS: MWWC) Big Move Up as Co Says Share Buy Back on Twitter as Minosis Token Goes Live Globally and $MNS is Heavily Traded

Published

on

Marketing Worldwide Corp (OTCMKTS: MWWC) is making an explosive move up the charts in recent days rocketing up 85% on Friday on about $800,000 dollar volume. On a day that the DOW lost 880 points and many large cap Companies lost billions in market valuation MWWC shareholders made out like bandits as the Minosis token $MNS went live and while it has not seen a significant amount of price action the $MNS token is trading heavily with hundreds of thousands of dollars changing hands on its first day and the telegram group is growing rapidly with almost 5,000 members.  Earlier this year MWWC announced the official launch of its highly anticipated Minosis.io crypto-mining platform. The Minosis.io crypto-mining platform was built on the smart idea of CEO Jason Schlenk of bringing Crypto Mining to the masses and it’s a really great idea. Last year when he took control of the Company and we wrote about it he said: “There is a clear gap between the people that know how to mine cryptocurrency, and the people that don’t. If you were to ask anyone if they were interested in making a passive income, they would undoubtedly say yes. So why are there only a select group of people who are taking advantage of the best possible opportunity of this generation?”   

Jason Schlenk has accomplished a lot since taking over the Company. Long before the Company launched its BEP20 token $MNS and Minosis.io crypto-mining platform Mr. Schlink got the Company’s filings in order and took it to “pink current” on OTCMarkets. He also re domiciled the Company from Delaware to Wyoming and went to work on the share structure retiring 1.75 billion restricted shares of the outstanding common stock and moved the authorized shares from 10.9 billion to 4.5 billion. Currently the stock trades at a $9 million market valuation leaving a lot of room for growth. There is a lot of buzz since the Company tweeted on the MINOSIS twitter account: “Stock Buy Back Wallet filling up 👀!” with the rumor that management is going to use the profits from MINOSIS Token COIN to buyback MWWC shares. Indead the Minosis token $MNS is very active and has a lot of buyers and sellers trading it now 24 hours a day. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Marketing Worldwide Corp (OTCMKTS: MWWC) is focused on building disruptive technologies that change the world. At the core, Marketing Worldwide Corporation is an acquisition incubator, purchasing companies and patents built by passionate visionaries. Since new CEO Schlenk took over the Company MWWC has launched a crypto mining platform with its own BEP20 token $MNS. Minosis.io crypto-mining platform was built on the smart idea of CEO Jason Schlenk of bringing Crypto Mining to the masses and making crypto mining as simple as a few clicks. 

Earlier this year MWWC announced the official launch of its highly anticipated Minosis.io crypto-mining platform. The Company’s #Minosis Agent has completed key software updates to facilitate an easy-to-use feature that allows users to get mining with unprecedented speed and convenience, creating significant increased production opportunities. MWWC launched a campaign through trade publications and web-based forums and ‘PPC’ (pay-per-click) platforms targeting millions of #cryptocurrency enthusiasts; with the expectations of adding up to 250,000 users to the platform before year’s end. 

https://twitter.com/CryptoKing1st/status/1535657560836956165

To Find out the inside Scoop on MWWC Subscribe to Microcapdaily.com Right Now

MWWC

Currently, the Minosis platform is generating approximately $0.12 USD per day/ per user in transactions fees (net gains after expenses) for ‘MWWC’; which does not include accelerated hash rates or commercial equipment boosters that are expected to be added throughout the course of the year. 

Marketing Worldwide is actively negotiating with several server farms that provide hash rental as a service which can be offered ‘for a minimal fee’ to the Minosis users. A rapid expansion of the hash rental will attract new clients to the platform by creating a higher ROI option. The Company expects to triple its current hash availability by late May 2022. 

In April MWWC released the Version 5 #Minosis update; which includes the addition of Bitcoin Gold (BTG) to the mining pool. Marketing Worldwide has continued to update and develop the Minosis mining platform for the past 7 months, adding new features, #cryptocurrency, and advancing the control settings so that the average user can mine crypto easily and conveniently. Bitcoin Gold ‘BTG’ Is now a mineable coin on the #Minosis platform. The Company has developed and is deploying an aggressive marketing campaign to expand the user base.  Though targeted paid marketing, the company is seeing substantial growth in users. The Company plans to continue to add new coins to the Minosis platform regularly to keep it fresh for its growing user base. 

The Company has hired Luna Public Relations and Marketing firm to build the community around the upcoming launch of the #MiNOSiS token. Nikita Sachdev founded Luna PR in 2017, which quickly became an award-winning advising, marketing, and public relations agency. It is a full-stack digital marketing company with dozens of clients across the globe. With the use of their highly skilled team, Luna PR helps upcoming and established blockchain and crypto projects reach their full potential. 

CEO Jason Schlenk stated when he took over the Company and went into crypto: “There is a clear gap between the people that know how to mine cryptocurrency, and the people that don’t. If you were to ask anyone if they were interested in making a passive income, they would undoubtedly say yes. So why are there only a select group of people who are taking advantage of the best possible opportunity of this generation?”  Through our research process, it has been identified that in every demographic there are multiple levels of users who have varying skills and financial motivations. We are able to break these groups into three simple categories: ‘Casual Passive’, ‘Intermediate Users’, ‘Advanced Miners’. While maintaining the simplicity of the platform, users with larger processors or mining stations will be able to utilize the software as well, and earn additional income as a pool contributor or hash rate provider. To respond to this overwhelming demand for a streamlined platform, the Company has uniquely tailored the functionality and user experience (UX). Through simple to understand on-screen prompts and in-module access to F.A.Q. Marketing Worldwide has also ensured that the sign-up process is quick, and straight-forward as our future user demand. \”We have created the platform’s automated assistant which has been named as the \”Agent\” feature. This functionality will safely and securely scan your system, install the application and define your mining capabilities.” 

 For more on MWWC Subscribe Right Now!

Currently trading at a $9,435,154 market valuation MWWC has 3,628,905,549 shares outstanding, 1,050,215,057 of which are restricted leaving 2,578,690,492 free trading shares and a total float of 1,978,690,492 MWWC shares worth $5.1 million. The Company has little debt of $542,296 total liabilities, $416k of which is accounts payable. MWWC is an exciting story developing in small caps; the Companys new BEP20 token $MNS just went live globally and is very active trading hundreds of thousands of dollars and there are already close to 5,000 members on telegram. Earlier this year the Company launched the Minosis.io crypto-mining platform, built on the smart idea of new CEO Jason Schlenk of bringing Crypto Mining to the masses. MWWC recently reversed off $0.0007 lows and looks significantly oversold with a valuation under $10 million and recent highs over $0.02. We will be updating on MWWC when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MWWC either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.